Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several high-level label-consistent statements were made, but multiple key label specifics (malignancy/teratogenicity/contraception and exact 2-year treatment-cycle structure) were omitted or only partially supported by the provided excerpts. Some infection/monitoring details were not explicitly supported by the supplied label text.
Category Scores
Accurate Statements
Mavenclad is a prescription medicine containing cladribine.
Provided label context identifies MAVENCLAD as cladribine (10 mg tablets).
Mavenclad is used to treat adults with relapsing forms of multiple sclerosis (MS).
Indications and Usage (Section 1) states indicated for treatment of relapsing forms of MS in adults.
Mavenclad is intended to reduce relapse activity over time.
Supported generally by the indication for relapsing forms of MS (no specific relapse-language provided in excerpts, but no direct contradiction in supplied label).
Mavenclad is given in short treatment courses rather than continuous daily dosing.
Dosage and Administration indicates recommended cumulative dosage divided into 2 yearly treatment courses and each course divided into 2 treatment cycles.
Patients may receive additional dosing in a second year based on the prescribed schedule.
Dosage and Administration (2.2) describes 2 yearly treatment courses.
The exact timing and number of doses per year depend on the patient’s body weight and the specific prescriber instructions.
Dosage and Administration (2.2) describes cumulative dosage based on mg per kg body weight (timing/number per cycle not fully detailed in provided excerpts).
Mavenclad differs from other MS disease-modifying therapies by dosing approach (short courses with immune targeting rather than continuous daily or infusion schedules).
Label excerpts provided support the short-course structure (2 yearly courses; each course divided into cycles). 'immune targeting' is not stated in provided excerpts.
Mavenclad can cause blood count changes.
Laboratory Testing and Monitoring (2.5) requires CBC with differential including lymphocyte count and describes holding therapy if lymphocytes below 200 cells/µL.
Mavenclad carries an infection risk.
Not explicitly supported by the provided label excerpts.
Mavenclad treatment includes blood and immune-related monitoring before dosing and between treatment periods.
Laboratory Testing and Monitoring to Assess Safety (2.5) requires CBC with differential including lymphocyte count before initiating treatment courses, at 2 and 6 months after start of each course, and periodically thereafter.
Clinicians check for conditions that might increase risk (including infection status) before dosing.
Partially supported: (2.1) baseline cancer screening and (2.5) baseline labs; the provided excerpts do not specifically mention infection-status checks.
Unsupported Statements
Mavenclad targets immune cells involved in MS.
Not supported by the provided prescribing information excerpts.
Patients typically receive two treatment weeks in one year.
Not supported by the provided excerpts; only 'each treatment course is divided into 2 treatment cycles' is shown, with no statement of 'two treatment weeks in one year.'
Mavenclad generally should be avoided in patients with certain active infections.
No infection-specific contraindication/avoidance language is included in the provided label excerpts.
Mavenclad should be avoided in patients with immune suppression concerns that would raise the risk of serious infection.
No immune-suppression/serious infection avoidance language is included in the provided label excerpts.
Mavenclad requires careful screening before and during treatment.
General monitoring is supported (CBC schedule; pregnancy exclusion; cancer screening; MRI baseline), but the claim is too broad and includes elements not evidenced by excerpts (e.g., infection screening) without specific label support.
Patients need to report symptoms of infection promptly during treatment.
No patient instruction to report infection symptoms is included in the provided excerpts.
Immune effects from cladribine can lower the body’s ability to fight infections.
Not supported by the provided excerpts.
Dosing can be adjusted or delayed based on risk conditions, including infection status.
The label excerpt provided specifies holding therapy if lymphocyte count <200 cells/µL and other specific required actions (e.g., pregnancy exclusion, baseline MRI), but does not include infection-status-based delay/adjustment language in the supplied text.
Missing doses can affect treatment timing and effectiveness.
No statement about missed doses appears in the provided excerpts.
The prescribing team may adjust the plan based on where the patient is in the cycle, lab results, and safety considerations.
Partially supported by monitoring and holding therapy rules, but broad 'adjust the plan' language is not explicitly described in the provided excerpts.
Contradictions
Low
AI Statement
Mavenclad generally should be avoided in patients with certain active infections.
Label Reference
No provided contraindication/warning excerpt states this; also the label excerpts provided do not support the claim as written (treated as unsupported rather than directly contradicted).
Important Omissions
Boxed warning and pregnancy/reproductive potential contraception requirements (contraindicated in pregnant women and those who do not plan effective contraception; exclude pregnancy before each course; use contraception for specified durations; discontinue if pregnant).
Importance:
High
Malignancy risk and related boxed warning/cancer screening guidance; including contraindication in patients with current malignancy and instruction not to administer additional treatment in the next 2 years after completing 2 treatment courses due to malignancy risk.
Importance:
High
Baseline MRI requirement (within 3 months) prior to the first treatment course due to risk of PML (not mentioned).
Importance:
Moderate
Specific laboratory holding threshold for therapy (hold if lymphocyte count below 200 cells/µL) and CBC timing details (2 and 6 months after start of each course; periodically thereafter).
Importance:
Moderate
Limitation of use: not recommended for clinically isolated syndrome (CIS) due to safety profile (not mentioned).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response omits major boxed-warning and contraindication information regarding malignancy and teratogenicity/contraception. Several infection-related risk claims and monitoring/dose-adjustment statements are not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Major omissions of boxed warning (malignancies/teratogenicity) and key contraindications/reproductive precautions, plus unsupported infection-related statements not present in the supplied label excerpts.
Suggested Improvement
Include boxed-warning content and reproductive risk/contraception requirements; add malignancy counseling/cancer screening and the 'do not administer additional MAVENCLAD during the next 2 years' limitation after 2 courses; replace unsupported infection-specific claims with label-supported monitoring (CBC/lymphocyte counts with the stated hold threshold and CBC timing) and the baseline MRI requirement.